Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Pac Partners Healthcare Conference (April 2022)
11 slides from Atomo Diagnostics's conference presentation, Apr 6, 2022
Slide 1: Pac Partners Healthcare Conference
Atomo Diagnostics Limited Authorised by John Kelly, Managing Director Level 1, 3-5 George Street, Leichhardt, NSW 2040 Australia For personal use only Pac Partners Healthcare Conference 6 April 2022 ATOMO ATOMO DIAGNOSTICS DIAGNOSTICS LIMITED|| (ASX: LIMITED (ASX: AT1) AT1)
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on communications transmitted or otherwise made available to the recipient in information available as at the date of this presentation. The information in this connection with the oppor
Slide 3: Introduction
INTRODUCTION Atomo Diagnostics Limited (ASX: AT1) is an innovative medical For personal use only device diagnostics company supplying unique, integrated rapid diagnostic test (RDT) devices and finished point-of-care rapid tests to the global market Headquartered in Australia with international opera
Slide 4: Transforming the Rapid Testing Experience
TRANSFORMING THE RAPID TESTING EXPERIENCE HIV For personal use only FROM Traditional ‘bits in a box’ LFA kits TO Atomo’s user-friendly all-in-one solution Issues with standard rapid test kits Advantages of Atomo devices Low user satisfaction and regulatory challenges INNOVATIVE: One integrated devic
Slide 5: Unique Core Capabilities
UNIQUE CORE CAPABILITIES The intersection between Medical Devices & Diagnostics For personal use only Less IP Intensive IP Intensive More sales focused Atomo DNA Core Functionality Devices Finished Products Customer Delivery Point-of-Care Self Testing • Blood collection • Galileo • HIV • Atomo Direc
Slide 6: Atomo's Integrated Test Platforms
ATOMO’S INTEGRATED TEST PLATFORMS HIV For personal use only In Market Getting Ready for Market Galileo: supports professional & self test applications. WHO DaVinci Combo Self Test: Prequalified. • two unique assays in a single rapid test. • Metered sample volumes to each test strip • integrated reag
Slide 7: Atomo's Blackburn Swab Device
ATOMO’S BLACKBURN SWAB DEVICE HIV For personal use only Simplifying swab based rapid testing Large addressable market Supports a broad range of swab test applications Improved diagnostic performance All premix sample delivered* Easy accessory to implement Compatible with existing rapid cassettes Sim
Slide 8: Atomo's Strategic Focus
ATOMO’S STRATEGIC FOCUS HIV For personal use only Core Capabilities Innovation, Co-development & Commercialisation (device design, usability, manufacturability, IP, regulatory, co-commercialisation) Markets Infectious Consumer Health OEM Devices Diseases Testing (devices, components, Iicenses) & Wel
Slide 9: Telehealth: Established in the Market
TELEHEALTH: ESTABLISHED IN THE MARKET For personal use only Consumer Interest Investor Focus 76% Venture funding doubled now interested in for digital health 2019-2020, on track telehealth versus 11% to double again 2020-2021 usage in 2019 Provider Acceptance 64% $50B Regulatory and Reimbursement 80
Slide 10: Corporate Snapshot
CORPORATE SNAPSHOT • Strong revenue growth, with H1 FY22 sales of $7.0m, 53% higher For personal use only than the prior comparable period • Quality balance sheet, with >$30m in assets including $15.8m in cash on hand and no debt • Strong cash receipts, with $7.7m in cash inflows from customers in H
Slide 11: Highlights
HIGHLIGHTS In the US, telehealth as a share of medical consults went from 0.2% to 13% at the peak of the COVID-19 pandemic, and has For personal use only stabilised at ~6% of all consults* A proven innovator: commercialised the world’s first fully integrated rapid blood tests for at-home use Expansi
Atomo Diagnostics — Pac Partners Healthcare Conference (April 2022) on 6ix